

Quynh-Thu Le

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4158845/publications.pdf>

Version: 2024-02-01

165
papers

11,384
citations

47006

47
h-index

31849

101
g-index

169
all docs

169
docs citations

169
times ranked

12375
citing authors

#	ARTICLE	IF	CITATIONS
1	Nasopharyngeal carcinoma. Lancet, The, 2019, 394, 64-80.	13.7	1,667
2	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Tj ETQq0 0 0 rgBT / Overlock 10 T	13.7	879
3	Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology, 2014, 110, 172-181.	0.6	585
4	The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology, 2019, 16, 669-683.	27.6	454
5	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3365-3373.	1.6	449
6	p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 3930-3938.	1.6	313
7	Image-guided Hypo-fractionated Stereotactic Radiosurgery to Spinal Lesions. Neurosurgery, 2001, 49, 838-846.	1.1	298
8	Hypoxic gene expression and metastasis. Cancer and Metastasis Reviews, 2004, 23, 293-310.	5.9	287
9	Proposal for the 8th edition of the <sc>AJCC</sc>/<sc>UICC</sc> staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 546-558.	4.1	254
10	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy and Oncology, 2018, 126, 3-24.	0.6	244
11	An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Nonâ€Small Cell Lung Cancers. Clinical Cancer Research, 2006, 12, 1507-1514.	7.0	237
12	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. Journal of Clinical Oncology, 2005, 23, 8932-8941.	1.6	233
13	Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 156-164.	1.6	216
14	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 1143-1169.	1.6	216
15	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2018, 126, 25-36.	0.6	214
16	Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). Journal of Clinical Oncology, 2021, 39, 956-965.	1.6	195
17	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 840-859.	1.6	178
18	Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study. Journal of Clinical Oncology, 2011, 29, 2808-2814.	1.6	161

#	ARTICLE	IF	CITATIONS
19	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 618-627.	0.8	156
20	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2208-2215.	7.0	149
21	Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1046-1054.	0.8	145
22	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , 2016, 122, 3307-3315.	4.1	125
23	Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10756-10761.	7.1	121
24	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 167-175.	0.8	111
25	A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 5700-5707.	7.0	99
26	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 567-580.	0.8	96
27	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	8.2	94
28	Treatment of maxillary sinus carcinoma. <i>Cancer</i> , 1999, 86, 1700-1711.	4.1	93
29	Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	85
30	Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 52-58.	2.6	83
31	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 568-576.	0.8	75
32	Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 996-1001.	0.8	73
33	Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03. <i>Journal of Clinical Oncology</i> , 2009, 27, 4281-4286.	1.6	72
34	Clinical biomarkers for hypoxia targeting. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 351-362.	5.9	70
35	Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 766-778.	0.8	70
36	A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 872-884.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 89-99.	2.3	65
38	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. <i>Clinical Cancer Research</i> , 2014, 20, 5558-5569.	7.0	64
39	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 721-729.	0.8	64
40	Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4820-7.	7.1	63
41	Chemical Space Mimicry for Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 875-882.	5.4	63
42	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1044-1052.	0.8	61
43	Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 802-9.	1.1	61
44	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 2552-2557.	1.6	58
45	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	6.3	56
46	Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. <i>Cancer</i> , 2006, 106, 1940-1949.	4.1	54
47	Very high-energy electron (VHEE) beams in radiation therapy; Treatment plan comparison between VHEE, VMAT, and PPBS. <i>Medical Physics</i> , 2017, 44, 2544-2555.	3.0	54
48	Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2019, 37, 1578-1589.	1.6	50
49	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	10.7	45
50	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	7.1	44
51	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.8	42
52	Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA. <i>Nature Methods</i> , 2022, 19, 759-769.	19.0	42
53	Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 375-383.	0.8	40
54	Age Disparity in Palliative Radiation Therapy Among Patients With Advanced Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 224-230.	0.8	40

#	ARTICLE	IF	CITATIONS
55	Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004). <i>Clinical Cancer Research</i> , 2004, 10, 5418-5424.	7.0	39
56	Overview of Advances in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3225-3226.	1.6	39
57	Commutability of the Epstein-Barr Virus WHO International Standard across Two Quantitative PCR Methods. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3802-3804.	3.9	36
58	Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. <i>Scientific Reports</i> , 2016, 6, 31146.	3.3	36
59	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 687-699.	0.8	35
60	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	12.8	34
61	Emerging Treatment Paradigms in Radiation Oncology. <i>Clinical Cancer Research</i> , 2015, 21, 3393-3401.	7.0	33
62	Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4287-95.	7.0	31
63	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 667-677.	0.8	30
64	Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1472-1478.	2.0	29
65	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 338-343.	0.6	29
66	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1346-1354.	0.8	28
67	Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results Medicare analysis. <i>Cancer</i> , 2018, 124, 4486-4494.	4.1	28
68	Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504. <i>Journal of Clinical Oncology</i> , 2018, 36, 6010-6010.	1.6	28
69	Identification of Doxorubicin as an Inhibitor of the IRE1-XBP1 Axis of the Unfolded Protein Response. <i>Scientific Reports</i> , 2016, 6, 33353.	3.3	27
70	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). <i>Radiotherapy and Oncology</i> , 2016, 119, 454-460.	0.6	27
71	Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 327-336.	5.0	27
72	In Vivo 1H Magnetic Resonance Spectroscopy of Lactate in Patients With Stage IV Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1151-1157.	0.8	26

#	ARTICLE	IF	CITATIONS
73	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 617-625.	6.4	26
74	Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide. <i>Journal of the National Cancer Institute</i> , 2021, 113, 852-862.	6.3	26
75	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 294-301.e3.	2.6	25
76	Acridine Derivatives as Inhibitors of the IRE1-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2055-2065.	4.1	24
77	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.6	24
78	Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6279-6284.	7.1	23
79	Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 942-952.	0.8	23
80	Long-Term Results of Radiation Therapy Oncology Group 9903: A Randomized Phase 3 Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiation Therapy for Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 907-915.	0.8	22
81	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 362-371.	0.8	22
82	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. <i>European Journal of Cancer</i> , 2022, 162, 221-236.	2.8	22
83	Galectin-1 links tumor hypoxia and radiotherapy. <i>Glycobiology</i> , 2014, 24, 921-925.	2.5	21
84	Botulinum Toxin Confers Radioprotection in Murine Salivary Glands. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1190-1197.	0.8	21
85	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7078-7088.	7.0	21
86	Lysosomal trafficking mediated by Arl8b and BORC promotes invasion of cancer cells that survive radiation. <i>Communications Biology</i> , 2020, 3, 620.	4.4	21
87	Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. <i>Oral Oncology</i> , 2015, 51, 438-445.	1.5	20
88	Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
89	Identifying and Targeting Hypoxia in Head and Neck Cancer: A Brief Overview of Current Approaches. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S56-S58.	0.8	19
90	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. <i>Practical Radiation Oncology</i> , 2013, 3, 294-300.	2.1	19

#	ARTICLE	IF	CITATIONS
91	Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. <i>Cell Chemical Biology</i> , 2021, 28, 1206-1220.e6.	5.2	19
92	Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6073-6073.	1.6	19
93	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. <i>Oral Oncology</i> , 2019, 95, 106-114.	1.5	18
94	Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. <i>Cancer</i> , 2019, 125, 704-711.	4.1	18
95	Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. <i>Seminars in Radiation Oncology</i> , 2009, 19, 53-62.	2.2	16
96	A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers. <i>Oral Oncology</i> , 2015, 51, 1132-1137.	1.5	16
97	Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice?. <i>Oral Oncology</i> , 2018, 86, 19-24.	1.5	16
98	Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1331-1345.e1.	0.8	16
99	Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 604-615.	6.4	16
100	Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. <i>JAMA Network Open</i> , 2021, 4, e2110438.	5.9	15
101	Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6065-6065.	1.6	15
102	125 I-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1458-1464.	5.0	14
103	Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy. <i>Laryngoscope</i> , 2016, 126, 1977-1980.	2.0	14
104	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. <i>Cancer</i> , 2019, 125, 382-390.	4.1	14
105	Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. <i>Radiotherapy and Oncology</i> , 2021, 156, 201-208.	0.6	14
106	A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6050-6050.	1.6	12
107	Palliative Radiation Before Hospice: The Long and the Short of It. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 1070-1079.	1.2	11
108	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1708-1709.	1.6	11

#	ARTICLE	IF	CITATIONS
109	Robust Estimation of Electron Density From Anatomic Magnetic Resonance Imaging of the Brain Using a Unifying Multi-Atlas Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 849-857.	0.8	11
110	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , 2020, 126, 5263-5273.	4.1	11
111	The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF- κ B signaling. <i>Science Advances</i> , 2022, 8, eabh2445.	10.3	10
112	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2023, 84, 307-319.	0.8	10
113	Nonsurgical Therapy for Stages I and II Non-“Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 237-261.	2.2	9
114	Evaluation of a metal artifact reduction technique in tonsillar cancer delineation. <i>Practical Radiation Oncology</i> , 2012, 2, 27-34.	2.1	9
115	Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 775-783.	0.8	9
116	Lambda-Carrageenan Enhances the Effects of Radiation Therapy in Cancer Treatment by Suppressing Cancer Cell Invasion and Metastasis through Racgap1 Inhibition. <i>Cancers</i> , 2019, 11, 1192.	3.7	9
117	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. <i>Clinical Cancer Research</i> , 2020, 26, 2972-2985.	7.0	9
118	The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherapy in locally advanced (LA) head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6003-6003.	1.6	9
119	Nasopharyngeal and Oropharyngeal Carcinomas: Target Delineation, Therapy Delivery and Stereotactic Boost Procedures with Intensity-Modulated/ Image-Guided Radiation Therapy. , 2007, 40, 208-231.		8
120	The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited. <i>Cancer</i> , 2017, 123, 12-16.	4.1	8
121	A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1 \pm “XBP1 Activation. <i>Molecular Cancer Research</i> , 2018, 16, 745-753.	3.4	8
122	Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 161, 82-90.	1.9	8
123	Rab27b contributes to radioresistance and exerts a paracrine effect via epiregulin in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa091.	0.7	8
124	p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6007-6007.	1.6	8
125	Flexible radioluminescence imaging for FDG-guided surgery. <i>Medical Physics</i> , 2016, 43, 5298-5306.	3.0	7
126	Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. <i>Oral Oncology</i> , 2017, 71, 180-183.	1.5	7

#	ARTICLE	IF	CITATIONS
127	An International Consensus on the Design of Prospective Clinicalâ€“Translational Trials in Spatially Fractionated Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100866.	1.2	7
128	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. <i>JCO Precision Oncology</i> , 2017, 2017, 1-9.	3.0	6
129	Proton radiotherapy and treatment delay in head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2020, 130, E598-E604.	2.0	6
130	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores â€“ A pooled analysis of RTOG 0129 and 0522. <i>Oral Oncology</i> , 2021, 116, 105241.	1.5	6
131	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2882.	3.7	6
132	NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6023-6023.	1.6	6
133	Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 787-795.	0.8	6
134	JUPITERâ€™2 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps. <i>Cancer Communications</i> , 2022, 42, 56-59.	9.2	6
135	Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6011-6011.	1.6	5
136	The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer. <i>Cancer Research Communications</i> , 2022, 2, 725-738.	1.7	5
137	Pilot study of loss of the p53/p63 target gene PERP at the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3188-3196.	2.0	4
138	A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilimumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS6097-TPS6097.	1.6	4
139	Radiographic Extranodal Extension in Human Papillomavirus-Associated Oropharyngeal Carcinoma: Can it Help Tailor Treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1028-1029.	0.8	3
140	18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6563-6563.	1.6	3
141	Risk stratification after recurrence of human papillomavirus (HPV) â€“related and nonâ€“HPV â€“related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. <i>Head and Neck</i> , 2021, 44, 158.	2.0	3
142	The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma. <i>PET Clinics</i> , 2012, 7, 381-394.	3.0	2
143	Radiotherapy for adenoid cystic carcinomas of the head and neck: clinical outcomes and patterns of failure. <i>Journal of Radiation Oncology</i> , 2014, 3, 49-56.	0.7	2
144	Individualizing treatment for patients with nasopharyngeal cancer. <i>Cancer</i> , 2015, 121, 2671-2673.	4.1	2

#	ARTICLE	IF	CITATIONS
145	In Reply to Zoto Mustafayev and Ozyar. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1307.	0.8	2
146	The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience.. Journal of Clinical Oncology, 2014, 32, 6025-6025.	1.6	2
147	Effect of the extent of lymph node dissection on overall survival in patients treated for oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 6075-6075.	1.6	2
148	Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms.. Journal of Clinical Oncology, 2016, 34, 6024-6024.	1.6	2
149	Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.. Journal of Clinical Oncology, 2019, 37, 6010-6010.	1.6	2
150	Accelerated Fractionation: The End of the Era of the Large, "One Size Fits All" Trial for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 7-9.	0.8	1
151	Focus on the Number of Radiation Oncology Trials or on Clinical Relevance? Reply. JAMA Oncology, 2018, 4, 1791.	7.1	1
152	Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216.. Journal of Clinical Oncology, 2013, 31, TPS6099-TPS6099.	1.6	1
153	Feasibility of optimizing intensity-modulated radiation therapy plans based on measured mucosal dose adjacent to dental fillings and toxicity outcomes. Journal of Applied Clinical Medical Physics, 2018, 19, 444-452.	1.9	0
154	In Regard to Beadle and Anderson. International Journal of Radiation Oncology Biology Physics, 2018, 102, 229-230.	0.8	0
155	The role of Glial cell derived neurotrophic factor in head and neck cancer. PLoS ONE, 2020, 15, e0229311.	2.5	0
156	Reply to A. J. Cmelak et al and B. Kalra et al. Journal of Clinical Oncology, 2021, 39, 2734-2735.	1.6	0
157	Racial inequality with radiation oncology referral and treatment in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 470-470.	1.6	0
158	Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 6077-6077.	1.6	0
159	Outcomes of elderly patients treated for oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 6076-6076.	1.6	0
160	Prognostic value of mid-treatment total lesion glycolysis in p16+ oropharyngeal cancer.. Journal of Clinical Oncology, 2015, 33, 6047-6047.	1.6	0
161	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.. Journal of Clinical Oncology, 2016, 34, 8510-8510.	1.6	0
162	Comments on the Publication by Corkum et al on "Does 5 + 5mm Equal Better Radiation Treatment Plans in Head and Neck Cancers?" Advances in Radiation Oncology, 2020, 5, 140-141.	1.2	0

#	ARTICLE	IF	CITATIONS
163	Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.8	0
164	De-escalating elective nodal irradiation for nasopharyngeal carcinoma. Lancet Oncology, The, 2022, 23, 441-443.	10.7	0
165	Aldehyde dehydrogenase 3A1 deficiency leads to mitochondrial dysfunction and impacts salivary gland stem cell phenotype. , 2022, 1, .		0